Autolus Therapeutics
AUTL
99 hedge funds and large institutions have $747M invested in Autolus Therapeutics in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 5 closing their positions.
7,157% more call options, than puts
Call options by funds: $1.52M | Put options by funds: $21K
580% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 5
189% more capital invested
Capital invested by funds: $258M → $747M (+$489M)
39% more funds holding
Funds holding: 71 → 99 (+28)
11% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 19
2.67% more ownership
Funds ownership: 64% → 66.67% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$19.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.4M |
| 4 |
PA
Perceptive Advisors
New York
|
+$6.98M |
| 5 |
FAM
Fred Alger Management
New York
|
+$5.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
-$15.3M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$11.9M |
| 3 |
AC
Armistice Capital
New York
|
-$11.6M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$6.85M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$2.81M |
AUTL Hedge Fund Activity: Q4 2023 in Review
99 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q4 2023, worth a combined $747M — up 189% from $258M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new AUTL positions and 5 closed out — a net gain of 29 holders — while 21 added to existing stakes and 19 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $19.3M. The largest seller was TFG Asset Management, cutting an estimated $15.3M.
- 99 institutional investors held Autolus Therapeutics (AUTL) as of Q4 2023, up from 71 in Q3 2023.
- Funds reported $747M of Autolus Therapeutics stock for Q4 2023, up 189% quarter-over-quarter.
- 34 funds opened new Autolus Therapeutics positions in Q4 2023 and 5 closed out, a net change of +29 holders.
- The largest Autolus Therapeutics buyer in Q4 2023 was Cormorant Asset Management, an estimated $19.3M added.
- The largest Autolus Therapeutics seller in Q4 2023 was TFG Asset Management, an estimated $15.3M sold.
Based on aggregated 13F filings for Q4 2023.